Cargando…

Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries

SIMPLE SUMMARY: We described post-operative complications, pancreatic sequelae, and post-surgical progression/relapse of pancreatic neuroendocrine neoplasms (PNENs) in 43 patients with multiple endocrine neoplasia type 1 (MEN1), who underwent major or minimal pancreatic surgeries. The performance of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tonelli, Francesco, Marini, Francesca, Giusti, Francesca, Iantomasi, Teresa, Giudici, Francesco, Brandi, Maria Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605506/
https://www.ncbi.nlm.nih.gov/pubmed/37894286
http://dx.doi.org/10.3390/cancers15204919
_version_ 1785127090747604992
author Tonelli, Francesco
Marini, Francesca
Giusti, Francesca
Iantomasi, Teresa
Giudici, Francesco
Brandi, Maria Luisa
author_facet Tonelli, Francesco
Marini, Francesca
Giusti, Francesca
Iantomasi, Teresa
Giudici, Francesco
Brandi, Maria Luisa
author_sort Tonelli, Francesco
collection PubMed
description SIMPLE SUMMARY: We described post-operative complications, pancreatic sequelae, and post-surgical progression/relapse of pancreatic neuroendocrine neoplasms (PNENs) in 43 patients with multiple endocrine neoplasia type 1 (MEN1), who underwent major or minimal pancreatic surgeries. The performance of a more conservative intervention, compared to both pancreaticoduodenectomy (PD) and distal pancreatectomy (DP), was associated with the absence of post-surgical complications, but required further pancreas surgeries for tumor relapse in 40.0% of the operated cases. Our data showed that major pancreatic resections (PD and DP) were effective in both preventing tumoral progression and guaranteeing a long-term PNEN relapse-free survival time in most of N+ and/or M+ patients. ABSTRACT: Pancreatic neuroendocrine neoplasms (PNENs) affect over 80% of patients with multiple endocrine neoplasia type 1 (MEN1). Surgery is usually the therapy of choice, but the real immediate and long-term therapeutic benefit of a partial extensive pancreatic resection remains controversial. We analyzed, in 43 PNEN MEN1 patients who underwent 19 pancreaticoduodenectomies (PD), 19 distal pancreatectomies (DP), and 5 minimal pancreatectomies, the prevalence of surgery-derived early complications and post-operative pancreatic sequelae, and the PNEN relapse-free survival time after surgery, comparing major (PD+DP) and minimal pancreatic surgeries. No post-operative mortality was observed. Metastatic cancers were found in 12 cases, prevalently from duodenal gastrinoma. Long-term cure of endocrine syndromes, by the 38 major pancreatic resections, was obtained in 78.9% of gastrinomas and 92.9% of insulinomas. In only one patient, hepatic metastases, due to gastrinoma, progressed to death. Out of the 38 major surgeries, only one patient was reoperated for the growth of a new PNEN in the remnant pancreas. No functioning PNEN persistence was reported in the five minimal pancreatic surgeries, PNEN relapse occurred in 60% of patients, and 40% of cases needed further pancreatic resection for tumor recurrence. No significant difference in PNEN relapse-free survival time after surgery was found between major and minimal pancreatic surgeries.
format Online
Article
Text
id pubmed-10605506
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106055062023-10-28 Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries Tonelli, Francesco Marini, Francesca Giusti, Francesca Iantomasi, Teresa Giudici, Francesco Brandi, Maria Luisa Cancers (Basel) Article SIMPLE SUMMARY: We described post-operative complications, pancreatic sequelae, and post-surgical progression/relapse of pancreatic neuroendocrine neoplasms (PNENs) in 43 patients with multiple endocrine neoplasia type 1 (MEN1), who underwent major or minimal pancreatic surgeries. The performance of a more conservative intervention, compared to both pancreaticoduodenectomy (PD) and distal pancreatectomy (DP), was associated with the absence of post-surgical complications, but required further pancreas surgeries for tumor relapse in 40.0% of the operated cases. Our data showed that major pancreatic resections (PD and DP) were effective in both preventing tumoral progression and guaranteeing a long-term PNEN relapse-free survival time in most of N+ and/or M+ patients. ABSTRACT: Pancreatic neuroendocrine neoplasms (PNENs) affect over 80% of patients with multiple endocrine neoplasia type 1 (MEN1). Surgery is usually the therapy of choice, but the real immediate and long-term therapeutic benefit of a partial extensive pancreatic resection remains controversial. We analyzed, in 43 PNEN MEN1 patients who underwent 19 pancreaticoduodenectomies (PD), 19 distal pancreatectomies (DP), and 5 minimal pancreatectomies, the prevalence of surgery-derived early complications and post-operative pancreatic sequelae, and the PNEN relapse-free survival time after surgery, comparing major (PD+DP) and minimal pancreatic surgeries. No post-operative mortality was observed. Metastatic cancers were found in 12 cases, prevalently from duodenal gastrinoma. Long-term cure of endocrine syndromes, by the 38 major pancreatic resections, was obtained in 78.9% of gastrinomas and 92.9% of insulinomas. In only one patient, hepatic metastases, due to gastrinoma, progressed to death. Out of the 38 major surgeries, only one patient was reoperated for the growth of a new PNEN in the remnant pancreas. No functioning PNEN persistence was reported in the five minimal pancreatic surgeries, PNEN relapse occurred in 60% of patients, and 40% of cases needed further pancreatic resection for tumor recurrence. No significant difference in PNEN relapse-free survival time after surgery was found between major and minimal pancreatic surgeries. MDPI 2023-10-10 /pmc/articles/PMC10605506/ /pubmed/37894286 http://dx.doi.org/10.3390/cancers15204919 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tonelli, Francesco
Marini, Francesca
Giusti, Francesca
Iantomasi, Teresa
Giudici, Francesco
Brandi, Maria Luisa
Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries
title Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries
title_full Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries
title_fullStr Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries
title_full_unstemmed Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries
title_short Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative Complications and Tumor Progression between Major and Minimal Pancreatic Surgeries
title_sort pancreatic neuroendocrine tumors in men1 patients: difference in post-operative complications and tumor progression between major and minimal pancreatic surgeries
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605506/
https://www.ncbi.nlm.nih.gov/pubmed/37894286
http://dx.doi.org/10.3390/cancers15204919
work_keys_str_mv AT tonellifrancesco pancreaticneuroendocrinetumorsinmen1patientsdifferenceinpostoperativecomplicationsandtumorprogressionbetweenmajorandminimalpancreaticsurgeries
AT marinifrancesca pancreaticneuroendocrinetumorsinmen1patientsdifferenceinpostoperativecomplicationsandtumorprogressionbetweenmajorandminimalpancreaticsurgeries
AT giustifrancesca pancreaticneuroendocrinetumorsinmen1patientsdifferenceinpostoperativecomplicationsandtumorprogressionbetweenmajorandminimalpancreaticsurgeries
AT iantomasiteresa pancreaticneuroendocrinetumorsinmen1patientsdifferenceinpostoperativecomplicationsandtumorprogressionbetweenmajorandminimalpancreaticsurgeries
AT giudicifrancesco pancreaticneuroendocrinetumorsinmen1patientsdifferenceinpostoperativecomplicationsandtumorprogressionbetweenmajorandminimalpancreaticsurgeries
AT brandimarialuisa pancreaticneuroendocrinetumorsinmen1patientsdifferenceinpostoperativecomplicationsandtumorprogressionbetweenmajorandminimalpancreaticsurgeries